Gastric cancer (GC) is the fourth most common neoplasm and the second leading cause of cancer-related death worldwide. In Latin America (LA), the burden of this disease is higher and is the leading cause of cancer death in some countries. Chemotherapy is the standard treatment for advanced-stage GC. However, the best regimen for specific populations, such as LA, is as yet unknown. Cisplatin and fluoropyrimidine continue to be the standard of care in light of the findings of phase III studies, while docetaxel, cisplatin, and 5-fluorouracil (5-FU) are alternatives for patients with suitable overall health. Oxaliplatin or irinotecan with fluoropyrimidine can also be used in elderly patients who are not candidates for cisplatin, or have a limited performance status. This review examines studies conducted in LA. Patients from LA are under-represented in multicenter trials of chemotherapy and targeted therapies. The major challenges currently lie in implementing strategies in which patients are selected on the basis of regional, racial or molecular characteristics, to consider the molecular subtype of GC for enrolment, and in selecting patients according to prognostic factors to optimize the benefits of chemotherapy.
KeywordsAdvanced Gastric CancerChemotherapyTargeted TherapyMolecular ClassificationLatin America
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN. International Journal of Cancer, 127, 2893-2917. http://dx.doi.org/10.1002/ijc.25516
Anderson, W.F., Camargo, M.C., Fraumeni Jr., J.F., Correa, P., Rosenberg, P.S. and Rabkin, C.S. (2010) Age-Specific Trends in Incidence of Noncardia Gastric Cancer in US Adults. JAMA, 303, 1723-1728. http://dx.doi.org/10.1001/jama.2010.496
Mathers, C.D. and Loncar, D. (2006) Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Medicine, 3, e442. http://dx.doi.org/10.1371/journal.pmed.0030442
Ennis, S.R., Rios-Vargas, M. and Albert, N.G. (2011) The Hispanic Population: 2010: 2010 Census Briefs. United States Census Bureau, Washington DC.
Bertuccio, P., Chatenoud, L., Levi, F., Praud, D., Ferlay, J., Negri, E., Malvezzi, M. and La Vecchia, C. (2009) Recent Patterns in Gastric Cancer: A Global Overview. International Journal of Cancer, 125, 666-673. http://dx.doi.org/10.1002/ijc.24290
Departamento de Estadísticas e Información de Salud (2014) Series y gráficos de mortalidad. www.deis.cl/?p=2543
Dassen, A.E., Lemmensm, V.E., van de Poll-Franse, L.V., Creemers, G.J., Brenninkmeijer, S.J., Lips, D.J., Wurff, V.D., Bosscha, K. and Coebergh J.W. (2010) Trends in Incidence, Treatment and Survival of Gastric Adenocarcinoma between 1990 and 2007: A Population-Based Study in the Netherlands. European Journal of Cancer, 46, 1101-1110. http://dx.doi.org/10.1016/j.ejca.2010.02.013
Zilberstein, B., Malheiros, C., Lourenco, L., Kassab, P., Jacob, C.E., Weston, A.C., Bresciani, C.J., Castro, O., Gama-Rodriguez, J., do Consenso, G., et al. (2013) Brazilian Consensus in Gastric Cancer: Guidelines for Gastric Cancer in Brazil. Arquivos Brasileiros de Cirurgia Digestiva, 26, 2-6. http://dx.doi.org/10.1590/S0102-67202013000100002
Pyrhonen, S., Kuitunen, T., Nyandoto, P. and Kouri, M. (1995) Randomised Comparison of Fluorouracil, Epidoxorubicin and Methotrexate (FEMTX) plus Supportive Care with Supportive Care Alone in Patients with Non-Resectable Gastric Cancer. British Journal of Cancer, 71, 587-591. http://dx.doi.org/10.1038/bjc.1995.114
Murad, A.M., Santiago, F.F., Petroianu, A., Rocha, P.R., Rodrigues, M.A. and Rausch, M. (1993) Modified Therapy with 5-Fluorouracil, Doxorubicin, and Methotrexate in Advanced Gastric Cancer. Cancer, 72, 37-41. http://dx.doi.org/10.1002/1097-0142(19930701)72:1 3.0.CO;2-P
Glimelius, B., Ekstrom, K., Hoffman, K., Graf, W., Sjodén, P.O., Haglund, U., Svensson, C., Enander, L.K., Linné, T., Sellstrom, H. and Heuman, R. (1997) Randomized Comparison between Chemotherapy plus Best Supportive Care with Best Supportive Care in Advanced Gastric Cancer. Annals of Oncology, 8, 163-168. http://dx.doi.org/10.1023/A:1008243606668
Pardo, C., Murillo, R., Pineros, M. and Castro, M.á. (2003). Casos Nuevos de cáncer en el Instituto Nacional de Cancerología, Colombia, 2002. Revista Colombiana de Cancerología, 7, 4-19.
Wagner, A.D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J. and Fleig, W.E. (2010) Chemotherapy for Advanced Gastric Cancer. Cochrane Database of Systematic Reviews, 17, CD004064. http://dx.doi.org/10.1002/14651858.cd004064.pub3
Muller, B., Gallardo, J., González, P., Cazap, E., Carraro, S., Baeza, R., Garbino, C. and Villar, H. (2009) Conclusiones del Primer Consenso Latinoamericano en Cáncer Gástrico: Terapias perioperatorias y tratamiento paliativo. Revista Chilena de Cancerología y Hematología, 1, 1-4.
Lacave, A.J., Barón, F.J., Antón, L.M., Estrada, E., De Sande, L.M., Palacio, I., Esteban, E., Gracia, J.M., Bueza, J.M., Fernandez, O.A., et al. (1991) Combination Chemotherapy with Cisplatin and 5-Fluorouracil 5-Day Infusion in the Therapy of Advanced Gastric Cancer: A Phase II Trial. Annals of Oncology, 2, 751-754.
MacDonald, J.S., Schein, P.S., Woolley, P.V., Smythe, T., Ueno, W., Hoth, D., Smith, F., Boiron, M., Gisselbretch, C., Brunet, R. and Lagarde, C. (1980) 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric Cancer. Annals of Internal Medicine, 93, 533-536. http://dx.doi.org/10.7326/0003-4819-93-4-533
Wils, J.A., Klein, H.O., Wagener, D.J., Bleiberg, H., Reis, H., Korsten, F., Conroy, T., Fickers, M., Leyvraz, S. and Buyse, M. (1991) Sequential High-Dose Methotrexate and Fluorouracil Combined with Doxorubicin—A Step Ahead in the Treatment of Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. Journal of Clinical Oncology, 9, 827-831.
Webb, A., Cunningham, D., Scarffe, J.H., Harper, P., Norman, A., Joffe, J.K., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) Randomized Trial Comparing Epirubicin, Cisplatin, and Fluorouracil versus Fluorouracil, Doxorubicin, and Methotrexate in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 15, 261-267. http://dx.doi.org/10.1016/S0959-8049(97)86090-X
Vanhoefer, U., Rougier, P., Wilke, H., Ducreux, M.P., Lacave, A.J., Van Cutsem, E., Planker, M., Santos, J.G., Piedbois, P., Paillot, B., et al. (2000) Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin versus Etoposide, Leucovorin, and Fluorouracil versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology, 8, 2648-2657.
Ajani, J.A., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y. and Voznyi, E. (2007) Clinical Benefit with Docetaxel plus Fluorouracil and Cisplatin Compared with Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Cancer Adenocarcinoma: The V-325 Study Group. Journal of Clinical Oncology, 25, 3205-3209. http://dx.doi.org/10.1200/JCO.2006.10.4968
Ajani, J.A., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y. and Voznyi, E. (2007) Quality of Life with Docetaxel plus Cisplatin and Fluorouracil Compared with Cisplatin and Fluorouracil from a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. Journal of Clinical Oncology, 25, 3210-3216. http://dx.doi.org/10.1200/JCO.2006.08.3956
Inal, A., Kaplan, M.A., Kucukoner, M. and Isikdogan, A. (2012) Docetaxel and Cisplatin plus Fluorouracil Compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Retrospective Analysis of Single Institution. Neoplasma, 59, 233-236. http://dx.doi.org/10.4149/neo_2012_030
Wang, J., Xu, R., Li, J., Bai, Y., Liu, T., Jiao, S., Dai, G., Xu, J., Liu, Y., Fan, N., et al. (2016) Randomized Multicenter Phase III Study of a Modified Docetaxel and Cisplatin plus Fluorouracil Regimen Compared with Cisplatin and Fluorouracil as First-Line Therapy for Advanced or Locally Recurrent Gastric Cancer. Gastric Cancer, 19, 234-244.
Kang, Y.K., Kang, W.K., Shin, D.B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., et al. (2009) Capecitabine/Cisplatin versus 5-Fluorouracil/Cisplatin as First-Line Therapy in Patients with Advanced Gastric Cancer: A Randomised Phase III Noninferiority Trial. Annals of Oncology, 20, 666-673. http://dx.doi.org/10.1093/annonc/mdn717
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J. and Norman, A.R. (2008) Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. The New England Journal of Medicine, 358, 36-46. http://dx.doi.org/10.1056/NEJMoa073149
Al-Batran, S.E., Hartmann, J.T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N. and Wilhelm, G. (2008) Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin plus either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 26, 1435-1442. http://dx.doi.org/10.1200/JCO.2007.13.9378
Garrido, M., Melgoza, G., Galindo, H., Madrid, J., Sánchez, C., Nervi, B., Alvarez, M. and Orellana, E. (2007) Treatment of Advanced Gastric Cancer with Oxaliplatin plus 5-Fluorouracil/Leucovorin (FOLFOX-4 Chemotherapy). Revista Médica de Chile, 135, 1380-1387.
Garrido, M., Vicente Conesa, M.A., Carmona-Bayonas, A., Faez, L., Custodio, A., López, C., Visa, L., Gallego Plazas, J., Fernandez Arrojo, S., Ramchandani, A., et al. (2014) First-Line Chemotherapy for Patients with Gastroesophageal Adenocarcinoma in the Community Setting: A Multicenter Cohort of 418 Patients. Annals of Oncology, 25, iv232.
Luo, H.Y., Xu, R.H., Wang, F., Qiu, M.Z., Li, Y.H., Li, F.H., Zhou, Z.W. and Chen, X.Q. (2010) Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer. Chemotherapy, 56, 94-100. http://dx.doi.org/10.1159/000305256
Xiang, X.J., Zhang, L., Qiu, F., Yu, F., Zhan, Z.Y., Feng, M., Yan, J., Zhao, J.G. and Xiong, J.P. (2012) A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer. Chemotherapy, 58, 1-7. http://dx.doi.org/10.1159/000335585
Dank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., Wenczl, M., Goker, E., Cisar, L., Wang, K. and Bugat, R. (2008) Randomized Phase III Study Comparing Irinotecan Combined with 5-Fluorouracil and Folinic Acid to Cisplatin Combined with 5-Fluorouracil in Chemotherapy Naive Patients with Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction. Annals of Oncology, 19, 1450-1457. http://dx.doi.org/10.1093/annonc/mdn166
Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., Gornet, J.M., Aparicio, T., Nguyen, S., Azzedine, A., et al. (2014) Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. Journal of Clinical Oncology, 32, 3520-3526. http://dx.doi.org/10.1200/JCO.2013.54.1011
Cancer Genome Atlas Research Network (2014) Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature, 513, 202-209.
Lei, Z., Tan, I.B., Das, K., Deng, N., Zouridis, H., Pattison, S., Chua, C., Feng, Z., Guan, I.K., Ooi, C.H., et al. (2013) Identification of Molecular Subtypes of Gastric Cancer with Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. Gastroenterology, 145, 554-565. http://dx.doi.org/10.1053/j.gastro.2013.05.010
Corvalán, A., Akiba, S., Valenzuela, M.T., Cumsille, M.A., Koriyama, C., Argandona, J., Backhouse, C., Bal, M., Mena, F., Palma, M. and Eizuru, Y. (2005) Clinical and Molecular Features of Cardial Gastric Cancer Associated to Epstein Barr Virus. Revista Médica de Chile, 133, 753-760. http://dx.doi.org/10.4067/S0034-98872005000700001
Camargo, M.C., Kim, W.H., Chiaravalli, A.M., Kim, K.M., Corvalan, A.H., Matsuo, K., Yu, J., Sung, J.J., Herrera-Goepfert, R., Meneses-Gonzalez, F., et al. (2014) Improved Survival of Gastric Cancer with Tumour Epstein-Barr Virus Positivity: An International Pooled Analysis. Gut, 63, 236-243.
Beltran, B. and Yabar, A. (2010) Expresión de HER2 en Cancer Gástrico en el Perú. Revista de Gastroenterología del Perú, 30, 324-327
Roa, I., Slater, J., Carvajal, D., Schalper, K., de Toro, G., Ares, R., Game, A., León, J. and de Aretxabala, X. (2013) HER2 Gene Amplification and Overexpression in Advanced Gastric Cancer. Revista Médica de Chile, 141, 1411-1419. http://dx.doi.org/10.4067/S0034-98872013001100007
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M., Kim, W., Ochial, A., Ruschoff, J. and Henkel, T. (2008) Assessment of a HER2 Scoring System for Gastric Cancer: Results from a Validation Study. Histopathology, 52, 797-805. http://dx.doi.org/10.1111/j.1365-2559.2008.03028.x
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. http://dx.doi.org/10.1016/S0140-6736(10)61121-X
Hecht, J.R., Bang, Y.J., Qin, S., Chung, H.C., Xu, J.M., Park, J., Jeziorski, Y., Hoff, P., Sobrero, A., Salman, P., et al. (2013) Lapatinib in Combination with Capecitabine plus Oxaliplatin (CapeOx) in HER2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma (AC): The TRIO-013/LOGiC Trial. Journal of Clinical Oncology, 31, LBA4001.
Garrido, M., Fonseca, P.J., Vieitez, J.M., Frunza, M. and Lacave, A.J. (2014) Challenges in First Line Chemotherapy and Targeted Therapy in Advanced Gastric Cancer. Expert Review of Anticancer Therapy, 14, 887-900. http://dx.doi.org/10.1586/14737140.2014.915194
Lordick, F., Kang, Y.K., Chung, H.C., Salman, P., Oh, S.C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenki, V.M., Gorbunova, V., et al. (2013) Capecitabine and Cisplatin with or without Cetuximab for Patients with Previously Untreated Advanced Gastric Cancer (EXPAND): A Randomised, Open-Label Phase 3 Trial. The Lancet Oncology, 14, 490-499. http://dx.doi.org/10.1016/S1470-2045(13)70102-5
Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Frances, A., Okines, C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., et al. (2013) Epirubicin, Oxaliplatin, and Capecitabine with or without Panitumumab for Patients with Previously Untreated Advanced Oesophagogastric Cancer (REAL3): A Randomised, Open-Label Phase 3 Trial. The Lancet Oncology, 14, 481-489. http://dx.doi.org/10.1016/S1470-2045(13)70096-2
Ohtsu, A., Shah, M.A., Van Cutsem, E., Rha, S.Y., Sawaki, A., Park, S.R., Lim, H.Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) Bevacizumab in Combination with Chemotherapy as First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Journal of Clinical Oncology, 29, 3968-3976. http://dx.doi.org/10.1200/JCO.2011.36.2236
Van Cutsem, E., de Haas, S., Kang, Y.K., Ohtsu, A., Tebbutt, N.C., Xu, J.M., Yong, W.P., Langer, B., Delmar, P., Scherer, S.J. and Shah, M.A. (2012) Bevacizumab in Combination with Chemotherapy as First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation from the AVAGAST Randomized Phase III Trial. Journal of Clinical Oncology, 30, 2119-2127. http://dx.doi.org/10.1200/JCO.2011.39.9824
Shen, L., Li, J., Xu, J., Pan, H., Dai, G., Qin, S., Wang, L., Wang, J., Yang, Z., Shu, Y., et al. (2015) Bevacizumab plus Capecitabine and Cisplatin in Chinese Patients with Inoperable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: Randomized, Double-Blind, Phase III Study (AVATAR Study). Gastric Cancer, 18, 168-176. http://dx.doi.org/10.1007/s10120-014-0351-5
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G. and Shimada, Y. (2014) Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial. The Lancet Oncology, 15, 1224-1235. http://dx.doi.org/10.1016/S1470-2045(14)70420-6
Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R. and Goswami, C. (2014) Ramucirumab Monotherapy for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (REGARD): An International, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 383, 31-39. http://dx.doi.org/10.1016/S0140-6736(13)61719-5
Ohtsu, A., Ajani, J.A., Bai, Y.X., Bang, Y.J., Chung, H.C., Pan, H.M., Sahmoud, T., Shen, L., Yeh, K.H., Chin, K., et al. (2013) Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. Journal of Clinical Oncology, 31, 3935-3943. http://dx.doi.org/10.1200/JCO.2012.48.3552
Iveson, T., Donehower, R.C., Davidenko, I., Tjulandin, S., Deptala, A., Harrison, M., Nirni, S., Lakshmaiah, K., Thomas, A., Yiang, Y., et al. (2014) Rilotumumab in Combination with Epirubicin, Cisplatin, and Capecitabine as First-Line Treatment for Gastric or Oesophagogastric Junction Adenocarcinoma: An Open-Label, Dose De-Escalation Phase 1b Study and a Double-Blind, Randomised Phase 2 Study. The Lancet Oncology, 15, 1007-1018. http://dx.doi.org/10.1016/S1470-2045(14)70023-3
Chau, I., Norman, A.R., Cunningham, D., Waters, J.S., Oates, J. and Ross, P.J. (2004) Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis from Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data. Journal of Clinical Oncology, 22, 2395-2403. http://dx.doi.org/10.1200/JCO.2004.08.154
Chau, I., Ashley, S. and Cunningham, D. (2009) Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data from the REAL 2 Study. Journal of Clinical Oncology, 27, e3-e4.
Polee, M.B., Hop, W.C., Kok, T.C., Eskens, F.A., van der Burg, M.E., Splinter, T.A., Siersema, P.D., Tilanus, H.W., Stoter, G. and van der Gaast, A. (2003) Prognostic Factors for Survival in Patients with Advanced Esophageal Cancer Treated with Cisplatin-Based Combination Chemotherapy. British Journal of Cancer, 89, 2045-2050. http://dx.doi.org/10.1038/sj.bjc.6601364
Kim, J.G., Ryoo, B.Y., Park, Y.H., Kim, B.S., Kim, T.Y., Im, Y.H. and Kang, Y.K. (2008) Prognostic Factors for Survival of Patients with Advanced Gastric Cancer Treated with Cisplatin-Based Chemotherapy. Cancer Chemotherapy and Pharmacology, 61, 301-307. http://dx.doi.org/10.1007/s00280-007-0476-x
Lee, J., Lim, T., Uhm, J.E., Park, K.W., Park, S.H., Lee, S.C., Park, J.O., Lim, H.Y., Sohn, T.S., et al. (2007) Prognostic Model to Predict Survival Following First-Line Chemotherapy in Patients with Metastatic Gastric Adenocarcinoma. Annals of Oncology, 18, 886-891. http://dx.doi.org/10.1093/annonc/mdl501
Vicente Conesa, M.A., Faez, L., Garrido, M., Custodio, A., López, C., Visa, L., Visa, L., Gallego, J., Fernandez, S., Ramchandani, A., et al. (2014) Prognostic Evaluation of a Multicenter Cohort of 484 Patients with Metastatic Gastroesophageal Adenocarcinoma. Annals of Oncology, 25, iv210-iv253.